BridgeBio Pharma reports incentive grants pursuant to Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Sept. 6, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on September 4, 2024, the Compensation Committee of BridgeBio's Board of Directors approved the grant of shares to 123 new employees in the form of restricted stock units totaling 359,926 shares of the Company's common stock. One-quarter of the shares underlying each employee's restricted stock units will vest on August 16, 2025, while one-twelfth of the remaining shares underlying each employee's restricted stock units will vest quarterly thereafter, in each case subject to the employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the awards described above were granted under BridgeBio’s amended and restated 2019 Inducement Equity Plan (the “Plan”).

The awards described above were each made as an incentive to employees entering into employment with the Company pursuant to Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's Board of Directors in November 2019 and amended and restated on February 10, 2023 and December 13, 2023.